Skip to main content

Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis

    Basic Details
    Date Posted
    Monday, November 14, 2022
    Medical Product

    In this report, we identified pregnancies exposed to ixekizumab (an interleukin-17A monoclonal antibody) and comparator drugs of interest among females regardless of indication and among females with approved ixekizumab indications in the Sentinel Distributed Database (SDD). The study period includes data from March 22, 2016 to June 30, 2021. We distributed this request to six Sentinel Data Partners on March 3, 2022.

    Additional Details
    FDA Center
    Time Period
    March 22, 2016 - June 30, 2021
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Females 15 to 45 years of age
    Data Sources
    Sentinel Distributed Database (SDD)